The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC
description
Transcript of The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC
![Page 1: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/1.jpg)
The Role of Neoadjuvant and Adjuvant Chemotherapy in
Muscle Invasive Bladder TCC
Scott North, MD, FRCPC, MHPEAssociate Professor, Dept. of Oncology, University of Alberta
Medical Oncologist, Cross Cancer InstituteEdmonton, AB
ACOGJune 24, 2011
![Page 2: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/2.jpg)
Disclosure
• Honoraria received from Amgen, Pfizer, Novartis, Janssen-Ortho
![Page 3: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/3.jpg)
Objectives
• Discuss the scope of the problem• Discuss potential advantages and
disadvantages of perioperative chemotherapy approaches
• Review the pertinent literature of perioperative chemotherapy use
• Discuss ongoing projects to optimally select patients for treatment
• Review one center’s “real world” experience
![Page 4: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/4.jpg)
Transitional Cell Carcinoma (TCC) in Canada
• Canadian Cancer Society 2010 statistics– 7,100 new cases– 1,850 deaths
• 75% of new cases will be superficial TCC• 25% of cases will be muscle invasive or
extravesical• Patients with superficial disease can
progress to muscle invasive disease over time
![Page 5: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/5.jpg)
Peri-operative chemotherapyRationale
• TCC is really two separate disease entities– Superficial versus muscle invasive
• Patients often perceive superficial disease as an “annoyance” and not a serious threat– 75% 5 y OS1
• Once disease is muscle invasive, the stakes are much higher and mortality is significant– 30-70% 5 y OS1 depending on depth of invasion (T2
versus higher)
1. US NCI, cancer.gov
![Page 6: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/6.jpg)
Peri-operative chemotherapyRationale
• Deaths from TCC are generally not local events
• Patients die as a result of metastatic disease• Local interventions will not deal with micro-
metastatic disease• Systemic therapy must be given to eradicate
micrometastatic disease in order to improve cure rates
![Page 7: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/7.jpg)
Peri-operative chemotherapyRationale
• For many malignancies, there is clear cut evidence for the order of therapies– colon cancer: surgery first then
chemotherapy later– Inflammatory breast cancer: chemo first then
local therapy• For a long time, there was little evidence
to guide us in TCC as to optimal sequencing
![Page 8: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/8.jpg)
Rationale for Adjuvant Therapy
• If the bladder is the problem, deal with it immediately
• Chemotherapy decisions can be based on true pathology
• If perioperative treatment benefit is modest, complete the most important modality of therapy first
• Surgery is a “stress test” that gives you info about tolerance for chemo
![Page 9: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/9.jpg)
Rationale for Neoadjuvant Therapy
• Give systemic therapy when the pelvic blood supply is intact
• in vivo chemo-sensitivity trial• Deal with micrometastatic disease
immediately• Patient is fitter and more able to tolerate
chemotherapy
![Page 10: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/10.jpg)
Adjuvant Chemotherapy• Multiple trials
– Small patient numbers ranging from 49-102– Two trials suggest survival benefit– Skinner et al. J Urol 1991
• 91 patients• Included T3-4 or node positive patients• Randomized to 4 cycles of cis/doxo/cyclo or
observation• Median survival
– 4.3 yrs chemo p=0.006– 2.4 yrs observation
• Criticized - ? selection bias:– 91 of 498 patients screened were eligible
Skinner DG et al, J Urol. 1991 Mar;145(3):459-64
![Page 11: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/11.jpg)
Adjuvant Chemotherapy• Stockle et al. J Urol 19951, BJU 20062
– High risk patients randomized to:• Cystectomy• Cystectomy + MVAC (or MVEC)
– Terminated early - only 49 patients as interim analysis showed significant improved 3 yrs survival
• 63% vs 13% p=0.002– 10 yr survival data still favours chemo group
• Progression free survival 44 vs13% p=0.002• Tumour specific survival 42 vs17% p=0.007• OS 27% vs 17% p=0.07
trend1. Stockle M et al, J Urol. 1995 Jan;153(1):47-52
2. Lehmann J, et al, BJU Int. 2006 Jan;97(1):42-7
![Page 12: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/12.jpg)
Adjuvant Chemotherapy
• 4 other trials – negativeHowever….– All small trials– Two trials only included bladder confined
disease – Inferior chemotherapy - single agent cisplatin
![Page 13: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/13.jpg)
Adjuvant chemotherapy• Meta analysis-
» Cochrane Collaboration 2006
– 491 pts. from 6 trials– Power limited
• Small numbers• Impact of trials stopped early• Patients not receiving allocated rx• Patients not receiving salvage chemotherapy
– Showed a relative decrease in death of 25% in favour of adjuvant chemotherapy (p=0.02)
– Absolute survival benefit: 9%
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD006018
![Page 14: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/14.jpg)
Neoadjuvant chemotherapy
• MRC trial (European) – 967 patients randomized to CMV vs no
chemotherapy– Definitive management of primary either
cystectomy or RT– 7 yr follow shows statistically significant
benefit with neoadjuvant chemotherapy– No subgroup analysis done to compare
cystectomy and RT groups
Lancet 354 (9178): 533-40, 1999
![Page 15: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/15.jpg)
Neoadjuvant Chemotherapy
• INT-0800(American) study» Confirmed results of MRC study
– 317 patients with T2 to T4a disease – Randomized to 3 cycles of neoadjuvant
MVAC prior to cystectomy or cystectomy alone
– Improved median survival by almost 3 years (77 months vs 46 months)
– Decreased risk of bladder cancer specific death by 25%
– Improved OS by 5% (p=0.06)Grossman et al, N Engl J Med 349 (9): 859-66, 2003
![Page 16: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/16.jpg)
Neoadjuvant Chemotherapy
• INT-0080 continued– Of long term survivors 85% had a
complete pathologic response at the time of cystectomy
– cPR rates• 38% in MVAC group• 15% in surgery alone group (post TURBT)• p=0.001
– Patients with T3 and T4 disease achieved the greatest survival benefit
![Page 17: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/17.jpg)
Neoadjuvant Chemotherapy
• Meta-analyses (3)– Advanced Cancer Meta-analysis
Collaboration• Included 2688 patients from 10 randomized
trials (did not include INT-0080)• Showed increased overall survival benefit of
5% at 5 yrs p=0.016 when neoadjuvant platinum based combination chemotherapy used
• Not significant if only single agent cisplatin trials were included
Advanced Bladder Cancer Meta-analysis Collaboration.: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361 (9373): 1927-34, 2003
![Page 18: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/18.jpg)
Neoadjuvant Chemotherapy
• Canadian Meta-analysis• Winquist et al
– 2605 patients in 11 trials with stage II or stage III disease
– 2-4 cycles of neoadjuvant chemo– Improved OS by 6.5% p=0.006– Mortality due to chemotherapy 1.1%
Winquist E, et al, J Urol. 2004 Feb;171(2 Pt 1):561-9
![Page 19: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/19.jpg)
Neoadjuvant Chemotherapy
• Advanced Bladder Cancer Meta-analysis collaboration– Now included 11 trials with 3005 patients– Included 98% of all known patients in
randomized trials using cisplatin based combination chemotherapy
– Improved OS by 5%; p=0.003– Decreased risk of death by 14%
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.Eur Urol. 2005 Aug;48(2):202-5
![Page 20: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/20.jpg)
Compare and Contrast
Neoadjuvant• Deals with micromets
sooner• Best evidence of
benefit• Concern re: delay in
surgery• ? Increased surgical
complications• Is benefit worth it?
Adjuvant• Treats only the highest
risk pts.• No delay in local Rx• Evidence of benefit is
weaker• Delays in healing may
preclude giving therapy• Is benefit worth it?
![Page 21: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/21.jpg)
Neoadjuvant chemotherapy
• Reasons for lack of wide acceptance:– Inaccuracies in staging—needless
chemotherapy– Delay in definitive surgery in patients that are
non-responders to chemotherapy– Is the 5% absolutely survival improvement
worth it?• Patient not referred or treated
![Page 22: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/22.jpg)
CPG’sDo they make a difference?
• Data was presented at the 2009 GU ASCO meeting regarding uptake of neoadjuvant consult requests in Alberta based on our guidelines– B. Miles, B. Eigl and others
• Two cohorts of muscle invasive TCC patients– Diagnosed within 18 mos. pre or post publication
of our guidelines recommending neoadjuvant treatment
![Page 23: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/23.jpg)
CPG impact
• Pre-Guidelines era– 2/107 (1.5%) of patients with presumptive >T2
TCC undergoing cystectomy were referred– No patient was offered any therapy pre-
operatively• Post-Guidelines era
– 23/129 (21.5%) were referred– 18/23 were offered treatment (cis/gem)
2009 Genitourinary Cancers Symposium, Feb 26-8, 2009, Orlando, FL, abstract #270
![Page 24: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/24.jpg)
CPG impact• While referral rates have improved, there is still
significant room for improvement• In Edmonton, our referral rate has picked up recently
– Approximately 2-3 patients/mo referred• Patient selection and discussion with Urology is
critical– Not all patients are appropriate for neoadjuvant treatment
• Urology comfort level with pre-op treatment is higher due to good results and lack of major perioperative complications
![Page 25: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/25.jpg)
Can we improve patient selection for neoadjuvant therapy?
• If global benefit is 5% improvement in survival, can we better target the population to treat?
• Should we only treat patients with extravesical disease on CT– Patients with pure T2 metastasize too– CT/MRI isn’t wonderful at clinical staging
![Page 26: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/26.jpg)
Who to treat?
• Pathological features– LVI?
• Genetic markers– p53 status?
• Other biomarkers– Area of research
• Novel markers• SNP’s• Nucleoside transporters
![Page 27: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/27.jpg)
What’s happening in the “real world”Neoadjuvant MO survey
• 30 Canadian medical oncologists were surveyed– 25 responded– 90% were academic based, 50% in practice >10
years– Half of respondents see 5-10 muscle invasive
patients/yr– 25% see >20 cases/yr
• Sample is skewed towards those who see lots of TCC patients
![Page 28: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/28.jpg)
Neoadjuvant bladder cancer survey
• All but one physician offered neoadjuvant therapy
• Patients who are offered neoadjuvant treatment:– Tend to be younger (<65)– Better PS (ECOG 0-1)– Good renal function (GFR >40)
• Most used GC, although 20% used HD-MVAC
![Page 29: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/29.jpg)
Neoadjuvant bladder cancer survey
• Despite MO willingness to treat, referrals nationally remain low
• Plan is to survey Urologists to see if they are referring or not
• Explore barriers to referral• Highlights the ever increasing multi-
disciplinary nature of disease management and need for good communication
![Page 30: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/30.jpg)
CCI Neoadjuvant Project
• All cases sent for neoadjuvant treatment who were treated and have cystectomy path available were reviewed
• 2007 to present day• TURBT info on 62 patients; cystectomy
path on 61 currently available• Clinical staging info based on Urology and
CT assessment available at baseline
![Page 31: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/31.jpg)
CCI Neoadjuvant Project
• Baseline TURBT (n=62):– T2: 30– T3: 29– T4: 3
• 46 men; 16 women• No age cutoff; oldest patient is 84• All received cisplatin based regimens
![Page 32: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/32.jpg)
CCI Neoadjuvant Project
• Cystectomy Pathology (n=61)– pT0: 17– pTis 7– pT1 3– pT2 or higher 34
• 28% are free of all cancer after Rx• 45% have no residual invasive disease
![Page 33: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/33.jpg)
CCI Neoadjuvant Project
• No patient who was deemed operable out the outset became inoperable due to time for chemo delivery
• No perioperative mortality• No anecdotal reporting of increased
perioperative morbidity• DFS and OS data still being collected
![Page 34: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/34.jpg)
CCI Neoadjuvant Project
• Significant pT0 rates can be achieved with GC– ?comparable to MVAC– This study is observational and not randomized
• “real life” experience in giving chemotherapy shows it is doable if patients are properly selected
• Once a good experience has occurred with one patient, it begets further referrals
![Page 35: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/35.jpg)
Neoadjuvant chemotherapyLessons learned
• Urologists and Med Oncs need to case conference invasive TCC patients
• Recognition that not all patients are good neoadjuvant chemo candidates is key
• We can’t presume to know what magnitude of benefit a patient thinks is “worth it” to proceed
• Having a case go smoothly dramatically increases referrals
![Page 36: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/36.jpg)
Conclusions
• Muscle invasive bladder cancer carries a significant risk of mortality
• Most deaths are due to systemic disease• Strength of evidence for perioperative
chemotherapy lies with neoadjuvant therapy
• Treatment should be a cisplatin-based combination therapy for a 12 week period
![Page 37: The Role of Neoadjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder TCC](https://reader035.fdocuments.net/reader035/viewer/2022062520/5681634a550346895dd3dc5c/html5/thumbnails/37.jpg)
Conclusions• Magnitude of benefit is similar to many other
oncology situations– Node negative breast cancer, high risk stage II colon
cancer• Despite evidence, referrals nationally are still low• Multidisciplinary care models are critical for good
outcomes• Hopefully in the future we will be able to better
select patients for therapy